ベータラクタムおよびベータラクタマーゼ阻害剤の世界市場に関する洞察、2028年までの予測Global Beta-lactam and Beta-lactamase Inhibitors Market Insights, Forecast to 2028 市場の分析と洞察。ベータラクタムおよびベータラクタマーゼ阻害剤の世界市場 COVID-19の大流行により、β-ラクタム薬およびβ-ラクタマーゼ阻害剤の世界市場規模は2022年に2億7730万米ドル、2028年には3億1119万... もっと見る
※当ページの内容はウェブ更新時の情報です。
サマリー市場の分析と洞察。ベータラクタムおよびベータラクタマーゼ阻害剤の世界市場COVID-19の大流行により、β-ラクタム薬およびβ-ラクタマーゼ阻害剤の世界市場規模は2022年に2億7730万米ドル、2028年には3億1119万米ドルに再調整されると予測され、予測期間2022-2028年にはCAGR 1.94% が予測されています。この健康危機による経済変化を十分に考慮すると、2021年にベータラクタムおよびベータラクタマーゼ阻害剤の世界市場の26.96%を占めるセファロスポリンは、2028年までに8344百万米ドルの価値を持つと予測されます。 世界のβ-ラクタムおよびβ-ラクタマーゼ阻害剤の範囲とセグメント ベータラクタムおよびベータラクタマーゼ阻害剤市場は、タイプ別および用途別に分類されます。世界のβ-ラクタムおよびβ-ラクタマーゼ阻害剤市場におけるプレイヤー、ステークホルダー、その他の参加者は、本レポートを強力なリソースとして利用することで、優位に立つことができるようになることでしょう。セグメント別分析では、2017年から2028年までのタイプ別、アプリケーション別の売上、収益、予測に焦点を当てます。 会社別 ファイザー ノバルティス(サンド) TEVA メルク AbbVie(アラガン) 大日本住友製薬 ヒグマ オーロビンド・ファーマ ウォックハート ルパン・リミテッド フレゼニウス・カビ B. ブラウン ユサンチビオティック 斉魯薬業 ACSドブファル 日医工(サジェント) アンチオティック 種類別セグメント ペニシリン系 セファロスポリン カルバペネム系抗生物質 モノバクタム系 組合せ 用途別セグメント 経口 静脈内注射 地域別セグメント 北アメリカ 米国 カナダ アジア太平洋地域 中国 日本 韓国 インド オーストラリア フィリピン インドネシア タイ マレーシア ヨーロッパ ドイツ フランス 英国 イタリア ロシア ラテンアメリカ メキシコ ブラジル アルゼンチン 中東・アフリカ トルコ サウジアラビア UAE 目次1 STUDY COVERAGE 1 1.1 Beta-lactam and Beta-lactamase Inhibitors Product Introduction 1 1.2 Market by Type 2 1.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 2 1.2.2 Penicillins 3 1.2.3 Cephalosporins 6 1.2.4 Carbapenems 8 1.2.5 Monobactams 10 1.3 Market by Application 12 1.3.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 12 1.3.2 Oral 13 1.3.3 Intravenous 13 1.4 Study Objectives 14 1.5 Years Considered 15 2 EXECUTIVE SUMMARY 16 2.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales Estimates and Forecasts 2017-2028 16 2.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Estimates and Forecasts 2017-2028 17 2.3 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Region: 2017 VS 2021 VS 2028 18 2.4 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Region 19 2.4.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Region (2017-2022) 19 2.4.2 Global Sales Beta-lactam and Beta-lactamase Inhibitors by Region (2023-2028) 21 2.5 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Region 22 2.5.1 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Region (2017-2022) 22 2.5.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Region (2023-2028) 23 2.6 North America 24 2.7 Europe 25 2.8 Asia-Pacific 26 2.9 Latin America 28 2.10 Middle East & Africa 29 3 COMPETITION BY MANUFACTURERS 31 3.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Manufacturers 31 3.1.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Manufacturers (2017-2022) 31 3.1.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Manufacturers (2017-2022) 32 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Beta-lactam and Beta-lactamase Inhibitors in 2021 33 3.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Manufacturers 34 3.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Manufacturers (2017-2022) 34 3.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Manufacturers (2017-2022) 35 3.2.3 Global Top 10 and Top 5 Companies by Beta-lactam and Beta-lactamase Inhibitors Revenue in 2021 36 3.3 Global Beta-lactam and Beta-lactamase Inhibitors Sales Price by Manufacturers (2017-2022) 38 3.4 Analysis of Competitive Landscape 38 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI) 38 3.4.2 Global Beta-lactam and Beta-lactamase Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 39 3.4.3 Global Beta-lactam and Beta-lactamase Inhibitors Manufacturers Geographical Distribution 41 3.5 Mergers & Acquisitions, Expansion Plans 43 4 MARKET SIZE BY TYPE 46 4.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Type 46 4.1.1 Global Beta-lactam and Beta-lactamase Inhibitors Historical Sales by Type (2017-2022) 46 4.1.2 Global Beta-lactam and Beta-lactamase Inhibitors Forecasted Sales by Type (2023-2028) 46 4.1.3 Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Type (2017-2028) 47 4.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Type 48 4.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Historical Revenue by Type (2017-2022) 48 4.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Forecasted Revenue by Type (2023-2028) 49 4.2.3 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Type (2017-2028) 49 4.3 Global Beta-lactam and Beta-lactamase Inhibitors Price by Type 50 4.3.1 Global Beta-lactam and Beta-lactamase Inhibitors Price by Type (2017-2022) 50 4.3.2 Global Beta-lactam and Beta-lactamase Inhibitors Price Forecast by Type (2023-2028) 51 5 MARKET SIZE BY APPLICATION 52 5.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Application 52 5.1.1 Global Beta-lactam and Beta-lactamase Inhibitors Historical Sales by Application (2017-2022) 52 5.1.2 Global Beta-lactam and Beta-lactamase Inhibitors Forecasted Sales by Application (2023-2028) 52 5.1.3 Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Application (2017-2028) 53 5.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Application 54 5.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Historical Revenue by Application (2017-2022) 54 5.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Forecasted Revenue by Application (2023-2028) 54 5.2.3 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Application (2017-2028) 54 5.3 Global Beta-lactam and Beta-lactamase Inhibitors Price by Application 56 5.3.1 Global Beta-lactam and Beta-lactamase Inhibitors Price by Application (2017-2022) 56 5.3.2 Global Beta-lactam and Beta-lactamase Inhibitors Price Forecast by Application (2023-2028) 56 6 NORTH AMERICA 57 6.1 North America Beta-lactam and Beta-lactamase Inhibitors Market Size by Type 57 6.1.1 North America Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2017-2028) 57 6.1.2 North America Beta-lactam and Beta-lactamase Inhibitors Revenue by Type (2017-2028) 58 6.2 North America Beta-lactam and Beta-lactamase Inhibitors Market Size by Application 59 6.2.1 North America Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2017-2028) 59 6.2.2 North America Beta-lactam and Beta-lactamase Inhibitors Revenue by Application (2017-2028) 60 6.3 North America Beta-lactam and Beta-lactamase Inhibitors Sales by Country 62 6.3.1 North America Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2017-2028) 62 6.3.2 North America Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2017-2028) 63 6.3.3 United States 64 6.3.4 Canada 65 7 EUROPE 66 7.1 Europe Beta-lactam and Beta-lactamase Inhibitors Market Size by Type 66 7.1.1 Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2017-2028) 66 7.1.2 Europe Beta-lactam and Beta-lactamase Inhibitors Revenue by Type (2017-2028) 67 7.2 Europe Beta-lactam and Beta-lactamase Inhibitors Market Size by Application 68 7.2.1 Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2017-2028) 68 7.2.2 Europe Beta-lactam and Beta-lactamase Inhibitors Revenue by Application (2017-2028) 69 7.3 Europe Beta-lactam and Beta-lactamase Inhibitors Market Size by Country 71 7.3.1 Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2017-2028) 71 7.3.2 Europe Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2017-2028) 72 7.3.3 Germany 74 7.3.4 U.K. 74 7.3.5 France 75 7.3.6 Italy 76 7.3.7 Russia 76 8 ASIA PACIFIC 78 8.1 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Size by Type 78 8.1.1 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2017-2028) 78 8.1.2 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Revenue by Type (2017-2028) 79 8.2 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Size by Application 80 8.2.1 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2017-2028) 80 8.2.2 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Revenue by Application (2017-2028) 81 8.3 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Size by Region 83 8.3.1 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Sales by Region (2017-2028) 83 8.3.2 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Revenue by Region (2017-2028) 85 8.3.3 China 87 8.3.4 Japan 87 8.3.5 South Korea 88 8.3.6 India 89 8.3.7 Australia 89 8.3.8 Indonesia 90 8.3.9 Thailand 91 8.3.10 Malaysia 92 8.3.11 Philippines 93 9 LATIN AMERICA 94 9.1 Latin America Beta-lactam and Beta-lactamase Inhibitors Market Size by Type 94 9.1.1 Latin America Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2017-2028) 94 9.1.2 Latin America Beta-lactam and Beta-lactamase Inhibitors Revenue by Type (2017-2028) 95 9.2 Latin America Beta-lactam and Beta-lactamase Inhibitors Market Size by Application 96 9.2.1 Latin America Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2017-2028) 96 9.2.2 Latin America Beta-lactam and Beta-lactamase Inhibitors Revenue by Application (2017-2028) 97 9.3 Latin America Beta-lactam and Beta-lactamase Inhibitors Market Size by Country 99 9.3.1 Latin America Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2017-2028) 99 9.3.2 Latin America Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2017-2028) 100 9.3.3 Mexico 102 9.3.4 Brazil 102 9.3.5 Argentina 103 10 MIDDLE EAST AND AFRICA 104 10.1 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Size by Type 104 10.1.1 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2017-2028) 104 10.1.2 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Revenue by Type (2017-2028) 105 10.2 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Size by Application 106 10.2.1 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2017-2028) 106 10.2.2 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Revenue by Application (2017-2028) 107 10.3 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Size by Country 109 10.3.1 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2017-2028) 109 10.3.2 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2017-2028) 110 10.3.3 Turkey 112 10.3.4 Saudi Arabia 112 10.3.5 UAE 113 11 COMPANY PROFILES 114 11.1 Pfizer 114 11.1.1 Pfizer Corporation Information 114 11.1.2 Pfizer Description and Business Overview 114 11.1.3 Pfizer Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 115 11.1.4 Pfizer Beta-lactam and Beta-lactamase Inhibitors Products Offered 115 11.2 Novartis (Sandoz) 119 11.2.1 Novartis (Sandoz) Corporation Information 119 11.2.2 Novartis (Sandoz) Description and Business Overview 119 11.2.3 Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 120 11.2.4 Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Products Offered 120 11.3 TEVA 124 11.3.1 TEVA Corporation Information 124 11.3.2 TEVA Description and Business Overview 124 11.3.3 TEVA Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 125 11.3.4 TEVA Beta-lactam and Beta-lactamase Inhibitors Products Offered 125 11.4 Merck 127 11.4.1 Merck Corporation Information 127 11.4.2 Merck Description and Business Overview 127 11.4.3 Merck Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 128 11.4.4 Merck Beta-lactam and Beta-lactamase Inhibitors Products Offered 128 11.5 AbbVie (Allergan) 128 11.5.1 AbbVie (Allergan) Corporation Information 128 11.5.2 AbbVie (Allergan) Description and Business Overview 129 11.5.3 AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 129 11.5.4 AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Products Offered 130 11.6 Sumitomo Dainippon 130 11.6.1 Sumitomo Dainippon Corporation Information 130 11.6.2 Sumitomo Dainippon Description and Business Overview 131 11.6.3 Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 131 11.6.4 Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Products Offered 132 11.7 Hikma 132 11.7.1 Hikma Corporation Information 132 11.7.2 Hikma Description and Business Overview 132 11.7.3 Hikma Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 133 11.7.4 Hikma Beta-lactam and Beta-lactamase Inhibitors Products Offered 133 11.8 Aurobindo Pharma 135 11.8.1 Aurobindo Pharma Corporation Information 135 11.8.2 Aurobindo Pharma Description and Business Overview 135 11.8.3 Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 135 11.8.4 Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Products Offered 136 11.9 Wockhardt 136 11.9.1 Wockhardt Corporation Information 136 11.9.2 Wockhardt Description and Business Overview 137 11.9.3 Wockhardt Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 137 11.9.4 Wockhardt Beta-lactam and Beta-lactamase Inhibitors Products Offered 137 11.10 Lupin Limited 138 11.10.1 Lupin Limited Corporation Information 138 11.10.2 Lupin Limited Description and Business Overview 138 11.10.3 Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 138 11.10.4 Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Products Offered 139 11.11 Fresenius Kabi 141 11.11.1 Fresenius Kabi Corporation Information 141 11.11.2 Fresenius Kabi Description and Business Overview 142 11.11.3 Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 142 11.11.4 Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Products Offered 143 11.12 B. Braun 143 11.12.1 B. Braun Corporation Information 143 11.12.2 B. Braun Description and Business Overview 144 11.12.3 B. Braun Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 144 11.12.4 B. Braun Beta-lactam and Beta-lactamase Inhibitors Products Offered 144 11.13 USantibiotics 145 11.13.1 USantibiotics Corporation Information 145 11.13.2 USantibiotics Description and Business Overview 146 11.13.3 USantibiotics Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 146 11.13.4 USantibiotics Beta-lactam and Beta-lactamase Inhibitors Products Offered 146 11.14 Qilu Pharmaceutical 147 11.14.1 Qilu Pharmaceutical Corporation Information 147 11.14.2 Qilu Pharmaceutical Description and Business Overview 147 11.14.3 Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 148 11.14.4 Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Products Offered 148 11.15 ACS Dobfar 149 11.15.1 ACS Dobfar Corporation Information 149 11.15.2 ACS Dobfar Description and Business Overview 149 11.15.3 ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 149 11.15.4 ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Products Offered 150 11.16 Nichi-Iko (Sagent) 151 11.16.1 Nichi-Iko (Sagent) Corporation Information 151 11.16.2 Nichi-Iko (Sagent) Description and Business Overview 152 11.16.3 Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 152 11.16.4 Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Products Offered 153 11.17 Antibiotice 156 11.17.1 Antibiotice Corporation Information 156 11.17.2 Antibiotice Description and Business Overview 156 11.17.3 Antibiotice Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 157 11.17.4 Antibiotice Beta-lactam and Beta-lactamase Inhibitors Products Offered 157 12 MARKET DRIVERS, OPPORTUNITIES, CHALLENGES FACTORS ANALYSIS 159 12.1 Beta-lactam and Beta-lactamase Inhibitors Industry Trends 159 12.2 Beta-lactam and Beta-lactamase Inhibitors Market Drivers 159 12.3 Beta-lactam and Beta-lactamase Inhibitors Market Challenges 160 13 VALUE CHAIN AND SALES CHANNELS ANALYSIS 161 13.1 Value Chain Analysis 161 13.2 Beta-lactam and Beta-lactamase Inhibitors Customers 161 13.3 Sales Channels Analysis 162 13.3.1 Sales Channels 162 13.3.2 Distributors 163 14 RESEARCH FINDINGS AND CONCLUSION 166 15 APPENDIX 167 15.1 Research Methodology 167 15.1.1 Methodology/Research Approach 167 15.1.2 Data Source 170 15.2 Author Details 172 15.3 Disclaimer 173
SummaryMarket Analysis and Insights: Global Beta-lactam and Beta-lactamase Inhibitors Market Table of Contents1 STUDY COVERAGE 1 1.1 Beta-lactam and Beta-lactamase Inhibitors Product Introduction 1 1.2 Market by Type 2 1.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 2 1.2.2 Penicillins 3 1.2.3 Cephalosporins 6 1.2.4 Carbapenems 8 1.2.5 Monobactams 10 1.3 Market by Application 12 1.3.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 12 1.3.2 Oral 13 1.3.3 Intravenous 13 1.4 Study Objectives 14 1.5 Years Considered 15 2 EXECUTIVE SUMMARY 16 2.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales Estimates and Forecasts 2017-2028 16 2.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Estimates and Forecasts 2017-2028 17 2.3 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Region: 2017 VS 2021 VS 2028 18 2.4 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Region 19 2.4.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Region (2017-2022) 19 2.4.2 Global Sales Beta-lactam and Beta-lactamase Inhibitors by Region (2023-2028) 21 2.5 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Region 22 2.5.1 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Region (2017-2022) 22 2.5.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Region (2023-2028) 23 2.6 North America 24 2.7 Europe 25 2.8 Asia-Pacific 26 2.9 Latin America 28 2.10 Middle East & Africa 29 3 COMPETITION BY MANUFACTURERS 31 3.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Manufacturers 31 3.1.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Manufacturers (2017-2022) 31 3.1.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Manufacturers (2017-2022) 32 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Beta-lactam and Beta-lactamase Inhibitors in 2021 33 3.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Manufacturers 34 3.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Manufacturers (2017-2022) 34 3.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Manufacturers (2017-2022) 35 3.2.3 Global Top 10 and Top 5 Companies by Beta-lactam and Beta-lactamase Inhibitors Revenue in 2021 36 3.3 Global Beta-lactam and Beta-lactamase Inhibitors Sales Price by Manufacturers (2017-2022) 38 3.4 Analysis of Competitive Landscape 38 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI) 38 3.4.2 Global Beta-lactam and Beta-lactamase Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 39 3.4.3 Global Beta-lactam and Beta-lactamase Inhibitors Manufacturers Geographical Distribution 41 3.5 Mergers & Acquisitions, Expansion Plans 43 4 MARKET SIZE BY TYPE 46 4.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Type 46 4.1.1 Global Beta-lactam and Beta-lactamase Inhibitors Historical Sales by Type (2017-2022) 46 4.1.2 Global Beta-lactam and Beta-lactamase Inhibitors Forecasted Sales by Type (2023-2028) 46 4.1.3 Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Type (2017-2028) 47 4.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Type 48 4.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Historical Revenue by Type (2017-2022) 48 4.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Forecasted Revenue by Type (2023-2028) 49 4.2.3 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Type (2017-2028) 49 4.3 Global Beta-lactam and Beta-lactamase Inhibitors Price by Type 50 4.3.1 Global Beta-lactam and Beta-lactamase Inhibitors Price by Type (2017-2022) 50 4.3.2 Global Beta-lactam and Beta-lactamase Inhibitors Price Forecast by Type (2023-2028) 51 5 MARKET SIZE BY APPLICATION 52 5.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Application 52 5.1.1 Global Beta-lactam and Beta-lactamase Inhibitors Historical Sales by Application (2017-2022) 52 5.1.2 Global Beta-lactam and Beta-lactamase Inhibitors Forecasted Sales by Application (2023-2028) 52 5.1.3 Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Application (2017-2028) 53 5.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Application 54 5.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Historical Revenue by Application (2017-2022) 54 5.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Forecasted Revenue by Application (2023-2028) 54 5.2.3 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Application (2017-2028) 54 5.3 Global Beta-lactam and Beta-lactamase Inhibitors Price by Application 56 5.3.1 Global Beta-lactam and Beta-lactamase Inhibitors Price by Application (2017-2022) 56 5.3.2 Global Beta-lactam and Beta-lactamase Inhibitors Price Forecast by Application (2023-2028) 56 6 NORTH AMERICA 57 6.1 North America Beta-lactam and Beta-lactamase Inhibitors Market Size by Type 57 6.1.1 North America Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2017-2028) 57 6.1.2 North America Beta-lactam and Beta-lactamase Inhibitors Revenue by Type (2017-2028) 58 6.2 North America Beta-lactam and Beta-lactamase Inhibitors Market Size by Application 59 6.2.1 North America Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2017-2028) 59 6.2.2 North America Beta-lactam and Beta-lactamase Inhibitors Revenue by Application (2017-2028) 60 6.3 North America Beta-lactam and Beta-lactamase Inhibitors Sales by Country 62 6.3.1 North America Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2017-2028) 62 6.3.2 North America Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2017-2028) 63 6.3.3 United States 64 6.3.4 Canada 65 7 EUROPE 66 7.1 Europe Beta-lactam and Beta-lactamase Inhibitors Market Size by Type 66 7.1.1 Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2017-2028) 66 7.1.2 Europe Beta-lactam and Beta-lactamase Inhibitors Revenue by Type (2017-2028) 67 7.2 Europe Beta-lactam and Beta-lactamase Inhibitors Market Size by Application 68 7.2.1 Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2017-2028) 68 7.2.2 Europe Beta-lactam and Beta-lactamase Inhibitors Revenue by Application (2017-2028) 69 7.3 Europe Beta-lactam and Beta-lactamase Inhibitors Market Size by Country 71 7.3.1 Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2017-2028) 71 7.3.2 Europe Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2017-2028) 72 7.3.3 Germany 74 7.3.4 U.K. 74 7.3.5 France 75 7.3.6 Italy 76 7.3.7 Russia 76 8 ASIA PACIFIC 78 8.1 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Size by Type 78 8.1.1 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2017-2028) 78 8.1.2 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Revenue by Type (2017-2028) 79 8.2 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Size by Application 80 8.2.1 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2017-2028) 80 8.2.2 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Revenue by Application (2017-2028) 81 8.3 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Size by Region 83 8.3.1 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Sales by Region (2017-2028) 83 8.3.2 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Revenue by Region (2017-2028) 85 8.3.3 China 87 8.3.4 Japan 87 8.3.5 South Korea 88 8.3.6 India 89 8.3.7 Australia 89 8.3.8 Indonesia 90 8.3.9 Thailand 91 8.3.10 Malaysia 92 8.3.11 Philippines 93 9 LATIN AMERICA 94 9.1 Latin America Beta-lactam and Beta-lactamase Inhibitors Market Size by Type 94 9.1.1 Latin America Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2017-2028) 94 9.1.2 Latin America Beta-lactam and Beta-lactamase Inhibitors Revenue by Type (2017-2028) 95 9.2 Latin America Beta-lactam and Beta-lactamase Inhibitors Market Size by Application 96 9.2.1 Latin America Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2017-2028) 96 9.2.2 Latin America Beta-lactam and Beta-lactamase Inhibitors Revenue by Application (2017-2028) 97 9.3 Latin America Beta-lactam and Beta-lactamase Inhibitors Market Size by Country 99 9.3.1 Latin America Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2017-2028) 99 9.3.2 Latin America Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2017-2028) 100 9.3.3 Mexico 102 9.3.4 Brazil 102 9.3.5 Argentina 103 10 MIDDLE EAST AND AFRICA 104 10.1 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Size by Type 104 10.1.1 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2017-2028) 104 10.1.2 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Revenue by Type (2017-2028) 105 10.2 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Size by Application 106 10.2.1 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2017-2028) 106 10.2.2 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Revenue by Application (2017-2028) 107 10.3 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Size by Country 109 10.3.1 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2017-2028) 109 10.3.2 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2017-2028) 110 10.3.3 Turkey 112 10.3.4 Saudi Arabia 112 10.3.5 UAE 113 11 COMPANY PROFILES 114 11.1 Pfizer 114 11.1.1 Pfizer Corporation Information 114 11.1.2 Pfizer Description and Business Overview 114 11.1.3 Pfizer Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 115 11.1.4 Pfizer Beta-lactam and Beta-lactamase Inhibitors Products Offered 115 11.2 Novartis (Sandoz) 119 11.2.1 Novartis (Sandoz) Corporation Information 119 11.2.2 Novartis (Sandoz) Description and Business Overview 119 11.2.3 Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 120 11.2.4 Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Products Offered 120 11.3 TEVA 124 11.3.1 TEVA Corporation Information 124 11.3.2 TEVA Description and Business Overview 124 11.3.3 TEVA Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 125 11.3.4 TEVA Beta-lactam and Beta-lactamase Inhibitors Products Offered 125 11.4 Merck 127 11.4.1 Merck Corporation Information 127 11.4.2 Merck Description and Business Overview 127 11.4.3 Merck Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 128 11.4.4 Merck Beta-lactam and Beta-lactamase Inhibitors Products Offered 128 11.5 AbbVie (Allergan) 128 11.5.1 AbbVie (Allergan) Corporation Information 128 11.5.2 AbbVie (Allergan) Description and Business Overview 129 11.5.3 AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 129 11.5.4 AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Products Offered 130 11.6 Sumitomo Dainippon 130 11.6.1 Sumitomo Dainippon Corporation Information 130 11.6.2 Sumitomo Dainippon Description and Business Overview 131 11.6.3 Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 131 11.6.4 Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Products Offered 132 11.7 Hikma 132 11.7.1 Hikma Corporation Information 132 11.7.2 Hikma Description and Business Overview 132 11.7.3 Hikma Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 133 11.7.4 Hikma Beta-lactam and Beta-lactamase Inhibitors Products Offered 133 11.8 Aurobindo Pharma 135 11.8.1 Aurobindo Pharma Corporation Information 135 11.8.2 Aurobindo Pharma Description and Business Overview 135 11.8.3 Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 135 11.8.4 Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Products Offered 136 11.9 Wockhardt 136 11.9.1 Wockhardt Corporation Information 136 11.9.2 Wockhardt Description and Business Overview 137 11.9.3 Wockhardt Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 137 11.9.4 Wockhardt Beta-lactam and Beta-lactamase Inhibitors Products Offered 137 11.10 Lupin Limited 138 11.10.1 Lupin Limited Corporation Information 138 11.10.2 Lupin Limited Description and Business Overview 138 11.10.3 Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 138 11.10.4 Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Products Offered 139 11.11 Fresenius Kabi 141 11.11.1 Fresenius Kabi Corporation Information 141 11.11.2 Fresenius Kabi Description and Business Overview 142 11.11.3 Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 142 11.11.4 Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Products Offered 143 11.12 B. Braun 143 11.12.1 B. Braun Corporation Information 143 11.12.2 B. Braun Description and Business Overview 144 11.12.3 B. Braun Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 144 11.12.4 B. Braun Beta-lactam and Beta-lactamase Inhibitors Products Offered 144 11.13 USantibiotics 145 11.13.1 USantibiotics Corporation Information 145 11.13.2 USantibiotics Description and Business Overview 146 11.13.3 USantibiotics Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 146 11.13.4 USantibiotics Beta-lactam and Beta-lactamase Inhibitors Products Offered 146 11.14 Qilu Pharmaceutical 147 11.14.1 Qilu Pharmaceutical Corporation Information 147 11.14.2 Qilu Pharmaceutical Description and Business Overview 147 11.14.3 Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 148 11.14.4 Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Products Offered 148 11.15 ACS Dobfar 149 11.15.1 ACS Dobfar Corporation Information 149 11.15.2 ACS Dobfar Description and Business Overview 149 11.15.3 ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 149 11.15.4 ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Products Offered 150 11.16 Nichi-Iko (Sagent) 151 11.16.1 Nichi-Iko (Sagent) Corporation Information 151 11.16.2 Nichi-Iko (Sagent) Description and Business Overview 152 11.16.3 Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 152 11.16.4 Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Products Offered 153 11.17 Antibiotice 156 11.17.1 Antibiotice Corporation Information 156 11.17.2 Antibiotice Description and Business Overview 156 11.17.3 Antibiotice Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2017-2022) 157 11.17.4 Antibiotice Beta-lactam and Beta-lactamase Inhibitors Products Offered 157 12 MARKET DRIVERS, OPPORTUNITIES, CHALLENGES FACTORS ANALYSIS 159 12.1 Beta-lactam and Beta-lactamase Inhibitors Industry Trends 159 12.2 Beta-lactam and Beta-lactamase Inhibitors Market Drivers 159 12.3 Beta-lactam and Beta-lactamase Inhibitors Market Challenges 160 13 VALUE CHAIN AND SALES CHANNELS ANALYSIS 161 13.1 Value Chain Analysis 161 13.2 Beta-lactam and Beta-lactamase Inhibitors Customers 161 13.3 Sales Channels Analysis 162 13.3.1 Sales Channels 162 13.3.2 Distributors 163 14 RESEARCH FINDINGS AND CONCLUSION 166 15 APPENDIX 167 15.1 Research Methodology 167 15.1.1 Methodology/Research Approach 167 15.1.2 Data Source 170 15.2 Author Details 172 15.3 Disclaimer 173
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(抗生物薬)の最新刊レポート
QYResearch社の抗生物薬分野での最新刊レポート
本レポートと同じKEY WORD(inhibitors)の最新刊レポート
よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/14 10:27 156.77 円 166.04 円 201.95 円 |